UK tech assessment
This article was originally published in The Gray Sheet
Executive Summary
Stakeholders affected by the impending seventh wave of the National Institute for Clinical Excellence work program should complete the NICE 1registration form before timetables are announced at the end of June. The UK Department of Health and the Welsh Assembly Government identify stakeholders as: patient organizations; health professional groups; and manufacturers with technologies in the clinical area covered by the scope of the program guidelines. Primary care organizations and acute trusts will be selected at random and invited to participate. NICE says that the assessment will include drug-eluting stent performance for atherosclerotic events and the prevention of restenosis (2"The Gray Sheet" May 27, 2002, p. 10)...
You may also be interested in...
Drug-Eluting Stents Added To NICE Technology Appraisal Program In UK
The UK National Institute for Clinical Excellence will release its timetable for a drug-eluting stent technology assessment by the end of June, according to Chief Executive Andrew Dillon
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.